Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature
Metrics: PDF 1235 views | HTML 1745 views | ?
Sheng Guo1, Dawei Chen1, Xuesong Huang1, Jie Cai1, Jean-Pierre Wery1, Qi-Xiang Li1,2
1Division of Translational Oncology, Crown Bioscience, Inc., Santa Clara, CA 95054, USA
2State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China
Qi-Xiang Li, email: email@example.com
Keywords: PDX, Erbitux, expression signature, patient stratification, biomarker
Received: December 10, 2015 Accepted: June 29, 2016 Published: July 8, 2016
Cetuximab is an approved treatment for metastatic colorectal carcinoma (mCRC) with codon 12/13-KRAS mutations, recently questioned for its validity, and alternative mutation-based biomarkers were proposed. We set out to investigate whether an expression signature can also predict response by utilizing a cetuximab mouse clinical trial (MCT) dataset on a cohort of 25 randomly selected EGFR+ CRC patient-derived xenografts (PDXs). While we found that the expression of EGFR and its ligands are not predictive of the cetuximab response, we tested a published RAS pathway signature, a 147-gene expression signature proposed to describe RAS pathway activity, against this MCT dataset. Interestingly, our study showed that the observed cetuximab activity has a strong correlation with the RAS pathway signature score, which was also demonstrated to have a certain degree of correlation with a historic clinical dataset. Altogether, the independent validations in unrelated datasets from independent cohort of CRCs strongly suggest that RAS pathway signature may be a relevant expression signature predictive of CRC response to cetuximab. Our data seem to suggest that an mRNA expressing signature may also be developed as a predictive biomarker for drug response, similarly to genetic mutations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.